Cost Considerations of Conversion from Aminoglycoside-Containing Combination Regimens to Ceftriaxone

Hayman JN Sbravati EC . Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions. Am J Hosp Pharm 1985; 42: 1343–7.

Rapp RP Bannon CL Bivins BA . The influence of dose frequency and agent toxicity on the cost of parenteral antibiotic therapy. Drug Intell Clin Pharm 1982; 16: 935–8.

Moore RD Smith CR Holloway JJ Lietman PS . Cefotaxime vs. nafcillin and tobramycin for the treatment of serious infection. Arch Intern Med 1986; 146: 1153–7.

Hoepelman IM Arska MR Verhoef J . Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet 1988; 1: 1305–9.

Mandell LA Bergeron MG Ronald AR , Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: A randomized, double-blind study. J Infect Dis 1989; 160: 433–41.

Briceland LL Nightingale CH Quintiliani R Cooper BW Smith KS . Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med 1988; 148: 2019–22.

Schentag JJ . Aminoglycosides. In: Evans WE Schentag JJ Jusko WJ , eds. Applied pharmacokinetics. Principles of therapeutic drug monitoring. San Francisco: Applied Therapeutics, 1980: 174–209.